Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market Intelligence.
Here's a review of the key developments from the period that contributed to the strong share-price movement:
Given the capital raise and sudden exits of two board members, it is understandable why shares took a step back in July.
Source: Fool.com
Intra-Cellular Therapies Inc. Stock
€70.50
-2.760%
The stock is an absolute favorite of our community with 49 Buy predictions and no Sell predictions.
With a target price of 85 € there is a positive potential of 20.57% for Intra-Cellular Therapies Inc. compared to the current price of 70.5 €.
